This report describes studies on the mechanism of eosinophilia in blood and bone marrow of a patient with untreated Addison's disease.
tsg/I00 ml, with no diurnal variation or increase after injection of 0.25 mg of an adrenocorticotrophic hormone analog, Synacthen (Ciba). The serum contained "yG antibodies to human adrenal tissue at a dilution of 1/20. There was no evidence of other endocrine disorder. There were no intrinsic factor antibodies, and the stomach produced normal amounts of acid in response to gastrin stimulation. The serum protein-bound iodine and vitamin BI2 levels were normal. The Mantoux test was negative at 1/1000. The stool did not contain parasites or ova.
Eosinophil production and half-life. Direct blood eosinophil counts were done by the method of Discombe (1) on venous blood before and after giving Synacthen, 0.25 mg intramuscularly, and cortisone, 25 mg orally, as shown in Fig. 1 . There was no alteration in blood eosinophil counts in response to Synacthen; however, 25 mg of cortisone reduced the blood eosinophil count from 780 to 230/mm3 4 hr later. When the patient began taking cortisone, 12.5 mg orally twice daily, the blood eosinophil level remained normal.
Bone marrow biopsies were done 6 hr before and 3 days after cortisone treatment was begun. The patient had given his full consent when the experimental character and nature of the biopsies had been explained. The bone marrow was taken from the sternum and put directly into a culture medium at 370C containing 8 ml of Parker 199 (Wellcome), 2 ml of isotonic phosphate buffer at pH 7.4, 1 ml of 50% glucose, and 1 ml of unheated isologous fresh serum taken 1.5 hr before sternal puncture, with 1 unit of heparin/ml. Marrow content of eosinophils declined by half, 3 days after steroids were begun, and the proportion of marrow eosinophils in DNA synthesis (S phase) declined by two-thirds. This is compatible with the possibility that steroids had decreased marrow eosinophil production, as the diminished labeling indicated fewer eosinophils in the cell cycle, possibly combined with S phase occupying a smaller proportion of the cell cycle time. Inasmuch as kinetic studies on rat bone marrow eosinophils have shown that alterations in production take 2 days to affect blood levels (4), it seems likely that the decrease in blood eosinophils in this patient came about by two actions of steroids: first, a direct effect on the circulating eosinophils and, later, a reduced rate of eosinophil production. The effect on eosinophil production may be mediated through an action on lymphocytes, as other studies in this laboratory have provided evidence that eosinophilia is mediated by lymphocytes and that agents which affect body stores of lymphocytes can block the eosinophil response to parasitic invasion (5, 6 ).
An eosinophilia is occasionally found in Addison's disease. Hills et al. (7) found that 4 of 26 patients with untreated Addison's disease had eosinophil counts greater than 500/mm3. They assumed that the eosinophilia was due to the low levels of circulating steroids, but, if this is so, it is surprising that eosinophilia is not a constant feature of Addison's disease. Autoantibodies to adrenal tissue have been described in 50% of patients with Addison's disease (8, 9) . West (10) described a patient with Addison's disease, due to tuberculosis, who had an eosinopenia. The patient described here had both an eosinophilia and adrenal antibodies, raising the possibility that an eosinophilia greater than 500/mm3 before treatment may occur in the autoallergic form of Addison's disease. We have been unable to find any other reports in which pretreatment eosinophil counts have been done in patients shown to have adrenal autoantibodies. Eosinophil counts after treatment has begun would not be helpful, as steroids affect the eosinophil count by the mechanism described in this patient. ACKNOWLEDGMENTS
